Oldest pages

Jump to navigation Jump to search

Showing below up to 250 results in range #251 to #500.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

  1. Connective tissue‏‎ (19:21, 12 September 2019)
  2. Consequential late effects‏‎ (19:21, 12 September 2019)
  3. Constancy test‏‎ (19:21, 12 September 2019)
  4. Contamination‏‎ (19:22, 12 September 2019)
  5. Coronary heart disease‏‎ (19:23, 12 September 2019)
  6. Cost-benefit analysis‏‎ (19:24, 12 September 2019)
  7. Coster-Kronig transition‏‎ (19:25, 12 September 2019)
  8. Curie‏‎ (19:25, 12 September 2019)
  9. Cytokines‏‎ (19:26, 12 September 2019)
  10. Decay constant‏‎ (19:28, 12 September 2019)
  11. Decommissioning‏‎ (19:28, 12 September 2019)
  12. Decontamination‏‎ (19:29, 12 September 2019)
  13. Decontamination factor‏‎ (19:29, 12 September 2019)
  14. Deontological Ethics‏‎ (19:30, 12 September 2019)
  15. Diastasis‏‎ (19:30, 12 September 2019)
  16. Dichotomous‏‎ (19:31, 12 September 2019)
  17. Differentiation‏‎ (19:31, 12 September 2019)
  18. In vivo radiobioassay‏‎ (19:32, 12 September 2019)
  19. Disposal‏‎ (19:33, 12 September 2019)
  20. DNA damage signalling‏‎ (19:33, 12 September 2019)
  21. Dose constraint‏‎ (19:35, 12 September 2019)
  22. Dose criteria‏‎ (19:35, 12 September 2019)
  23. Dose limit‏‎ (19:36, 12 September 2019)
  24. Dose per unit intake coefficient‏‎ (19:37, 12 September 2019)
  25. Dose rate‏‎ (19:38, 12 September 2019)
  26. Dose rate effectiveness factor‏‎ (19:38, 12 September 2019)
  27. Dose-rate effect‏‎ (19:39, 12 September 2019)
  28. Dose-threshold‏‎ (19:40, 12 September 2019)
  29. Early normal tissue responses‏‎ (19:43, 12 September 2019)
  30. Edema‏‎ (19:44, 12 September 2019)
  31. Effect Dose 50‏‎ (19:45, 12 September 2019)
  32. Effective charge number‏‎ (19:46, 12 September 2019)
  33. Effective dose equivalent‏‎ (19:47, 12 September 2019)
  34. Effective half-life‏‎ (19:49, 12 September 2019)
  35. Electron-capture decay‏‎ (19:49, 12 September 2019)
  36. Electrophysiology‏‎ (19:51, 12 September 2019)
  37. Emergency‏‎ (19:52, 12 September 2019)
  38. Emergency exposure situation‏‎ (19:52, 12 September 2019)
  39. Emergency plan‏‎ (19:53, 12 September 2019)
  40. Emergency preparedness‏‎ (19:53, 12 September 2019)
  41. Emergency procedures‏‎ (19:53, 12 September 2019)
  42. Endogeneous excretion‏‎ (19:54, 12 September 2019)
  43. Environmental exposure‏‎ (19:55, 12 September 2019)
  44. Environmental radiation protection‏‎ (19:55, 12 September 2019)
  45. Epithelium‏‎ (19:56, 12 September 2019)
  46. Erythropoietin‏‎ (19:57, 12 September 2019)
  47. Ethics‏‎ (19:58, 12 September 2019)
  48. Exempt waste‏‎ (19:59, 12 September 2019)
  49. Exemption level‏‎ (19:59, 12 September 2019)
  50. Existing exposure situation‏‎ (20:00, 12 September 2019)
  51. Exponential survival curve‏‎ (20:01, 12 September 2019)
  52. Exposure, external or internal‏‎ (20:01, 12 September 2019)
  53. Exposure situation‏‎ (20:02, 12 September 2019)
  54. Habitual mouth breather‏‎ (12:42, 13 September 2019)
  55. Habitual nose breather‏‎ (12:42, 13 September 2019)
  56. Half-life, physical‏‎ (12:43, 13 September 2019)
  57. Hazard‏‎ (12:43, 13 September 2019)
  58. Health Surveillance‏‎ (12:43, 13 September 2019)
  59. Heliosphere‏‎ (12:44, 13 September 2019)
  60. Hierarchical tissues‏‎ (12:44, 13 September 2019)
  61. High level waste‏‎ (12:45, 13 September 2019)
  62. Hormones‏‎ (12:45, 13 September 2019)
  63. Hyperbaric oxygen‏‎ (12:46, 13 September 2019)
  64. Hypertrophic cardiomyopathy‏‎ (12:48, 13 September 2019)
  65. Hypoplasia‏‎ (12:48, 13 September 2019)
  66. Immune system‏‎ (12:49, 13 September 2019)
  67. Incident‏‎ (12:50, 13 September 2019)
  68. Inclusiveness‏‎ (12:50, 13 September 2019)
  69. Individual decontamination‏‎ (12:50, 13 September 2019)
  70. Individual monitoring‏‎ (12:51, 13 September 2019)
  71. Individual-related‏‎ (12:51, 13 September 2019)
  72. Inhalability‏‎ (12:53, 13 September 2019)
  73. Inner bremsstrahlung‏‎ (12:53, 13 September 2019)
  74. Institutional control‏‎ (12:54, 13 September 2019)
  75. Intermediate level waste‏‎ (12:54, 13 September 2019)
  76. Internal conversion electron‏‎ (12:56, 13 September 2019)
  77. Interphase death‏‎ (12:56, 13 September 2019)
  78. Intervention Level‏‎ (12:56, 13 September 2019)
  79. Interventional procedure‏‎ (12:57, 13 September 2019)
  80. Iso-effect plots‏‎ (12:58, 13 September 2019)
  81. Isomers‏‎ (12:58, 13 September 2019)
  82. Isotropic geometry‏‎ (12:58, 13 September 2019)
  83. Itinerant (radiation) worker‏‎ (12:59, 13 September 2019)
  84. Latent time/period or latency interval‏‎ (13:01, 13 September 2019)
  85. Limitation of dose‏‎ (13:01, 13 September 2019)
  86. Lineal energy‏‎ (13:02, 13 September 2019)
  87. Linear-non-threshold model‏‎ (13:03, 13 September 2019)
  88. Low level waste‏‎ (13:08, 13 September 2019)
  89. Lymphatic system‏‎ (13:08, 13 September 2019)
  90. Macrophage colony stimulating factor‏‎ (13:08, 13 September 2019)
  91. Magnetosphere‏‎ (13:09, 13 September 2019)
  92. Member of the public‏‎ (13:10, 13 September 2019)
  93. Mendelian diseases‏‎ (13:10, 13 September 2019)
  94. Mitigation‏‎ (13:10, 13 September 2019)
  95. Multistage tumorigenesis‏‎ (13:11, 13 September 2019)
  96. Myocardial perfusion‏‎ (13:12, 13 September 2019)
  97. Myocardial stress test‏‎ (13:13, 13 September 2019)
  98. Naturally occurring radioactive material‏‎ (13:14, 13 September 2019)
  99. Necrosis‏‎ (13:14, 13 September 2019)
  100. Neurological syndrome‏‎ (13:14, 13 September 2019)
  101. Neurovascular syndrome‏‎ (13:15, 13 September 2019)
  102. Non-sphericity parameter‏‎ (13:16, 13 September 2019)
  103. Nuclear track detectors‏‎ (13:17, 13 September 2019)
  104. Particle radiance‏‎ (13:28, 13 September 2019)
  105. Peak skin dose‏‎ (13:28, 13 September 2019)
  106. Pelagic‏‎ (13:29, 13 September 2019)
  107. Percutaneous coronary intervention‏‎ (13:29, 13 September 2019)
  108. Pericarditis‏‎ (13:29, 13 September 2019)
  109. Pharynx‏‎ (13:30, 13 September 2019)
  110. Planned exposure situation‏‎ (13:30, 13 September 2019)
  111. Platelet-derived growth factor‏‎ (13:30, 13 September 2019)
  112. Practical radiological protection culture‏‎ (13:32, 13 September 2019)
  113. Prevailing circumstances‏‎ (13:32, 13 September 2019)
  114. Principle of application of dose limits‏‎ (13:32, 13 September 2019)
  115. Principle of justification‏‎ (13:33, 13 September 2019)
  116. Principle of optimisation‏‎ (13:33, 13 September 2019)
  117. Procedural values‏‎ (13:34, 13 September 2019)
  118. Progenitor cell‏‎ (13:35, 13 September 2019)
  119. Projected dose‏‎ (13:36, 13 September 2019)
  120. Protection strategy‏‎ (13:37, 13 September 2019)
  121. Protective action‏‎ (13:37, 13 September 2019)
  122. Protective action guide‏‎ (13:38, 13 September 2019)
  123. Public exposure‏‎ (13:39, 13 September 2019)
  124. Radiation modifier‏‎ (13:41, 13 September 2019)
  125. Radiation safety officer‏‎ (13:42, 13 September 2019)
  126. Radiation worker‏‎ (13:44, 13 September 2019)
  127. Radioactive dispersion device‏‎ (13:44, 13 September 2019)
  128. Radioactive source‏‎ (13:45, 13 September 2019)
  129. Radioactive substance‏‎ (13:46, 13 September 2019)
  130. Radioactivity‏‎ (13:46, 13 September 2019)
  131. Radiofrequency ablation‏‎ (13:46, 13 September 2019)
  132. Radiographer‏‎ (13:48, 13 September 2019)
  133. Radiological protection principles‏‎ (13:49, 13 September 2019)
  134. Radionuclides of natural origin‏‎ (13:49, 13 September 2019)
  135. Radioresponsiveness‏‎ (13:49, 13 September 2019)
  136. Radiosensitiser‏‎ (13:50, 13 September 2019)
  137. Radiosensitivity, cellular‏‎ (13:50, 13 September 2019)
  138. Reasonableness‏‎ (13:50, 13 September 2019)
  139. Recovery‏‎ (13:51, 13 September 2019)
  140. Recovery responder‏‎ (13:51, 13 September 2019)
  141. Reference bioassay function‏‎ (13:51, 13 September 2019)
  142. Reference biokinetic model‏‎ (13:52, 13 September 2019)
  143. Reference level‏‎ (13:52, 13 September 2019)
  144. Rehabilitation of living conditions‏‎ (13:52, 13 September 2019)
  145. Relocation‏‎ (13:53, 13 September 2019)
  146. Remedial action‏‎ (13:53, 13 September 2019)
  147. Remediation‏‎ (13:53, 13 September 2019)
  148. Repopulation‏‎ (13:54, 13 September 2019)
  149. Representative organism (non-human biota)‏‎ (13:54, 13 September 2019)
  150. Representative person‏‎ (13:54, 13 September 2019)
  151. Reproductive integrity‏‎ (13:55, 13 September 2019)
  152. Residual dose‏‎ (13:55, 13 September 2019)
  153. Respiratory protection‏‎ (13:55, 13 September 2019)
  154. Retrievability‏‎ (13:56, 13 September 2019)
  155. Reversibility‏‎ (13:56, 13 September 2019)
  156. Right to know‏‎ (13:57, 13 September 2019)
  157. Rigidity‏‎ (13:58, 13 September 2019)
  158. Routine monitoring‏‎ (13:58, 13 September 2019)
  159. Safety case‏‎ (13:59, 13 September 2019)
  160. Safety culture‏‎ (13:59, 13 September 2019)
  161. Scintigraphy‏‎ (13:59, 13 September 2019)
  162. Self-help protection‏‎ (14:00, 13 September 2019)
  163. Slow repair‏‎ (14:01, 13 September 2019)
  164. Solar cosmic radiation‏‎ (14:01, 13 September 2019)
  165. Solar cycle‏‎ (14:01, 13 September 2019)
  166. Solar particle event‏‎ (14:01, 13 September 2019)
  167. Source term‏‎ (14:02, 13 September 2019)
  168. Source-related‏‎ (14:02, 13 September 2019)
  169. South Atlantic anomaly‏‎ (14:03, 13 September 2019)
  170. Special (non-routine) monitoring‏‎ (14:03, 13 September 2019)
  171. Spontaneous fission‏‎ (14:03, 13 September 2019)
  172. Stakeholder‏‎ (14:04, 13 September 2019)
  173. Stenosis‏‎ (14:04, 13 September 2019)
  174. Storage‏‎ (14:04, 13 September 2019)
  175. Subcutaneous tissue‏‎ (14:05, 13 September 2019)
  176. Substantial radiation dose level‏‎ (14:05, 13 September 2019)
  177. Systemic model‏‎ (14:06, 13 September 2019)
  178. Tachycardia‏‎ (14:10, 13 September 2019)
  179. Target region‏‎ (14:10, 13 September 2019)
  180. Target tissue‏‎ (14:10, 13 September 2019)
  181. Telangiectasia‏‎ (14:11, 13 September 2019)
  182. Threshold dose for tissue reactions‏‎ (14:11, 13 September 2019)
  183. Thyroid blocking‏‎ (14:11, 13 September 2019)
  184. Time factor‏‎ (14:11, 13 September 2019)
  185. Tissue equivalent material‏‎ (14:12, 13 September 2019)
  186. Tolerability‏‎ (14:12, 13 September 2019)
  187. Track structure‏‎ (14:13, 13 September 2019)
  188. Transfer compartment‏‎ (14:14, 13 September 2019)
  189. Transfer rate‏‎ (14:14, 13 September 2019)
  190. Transforming growth factor‏‎ (14:15, 13 September 2019)
  191. Transparency‏‎ (14:15, 13 September 2019)
  192. Trapped particles‏‎ (14:16, 13 September 2019)
  193. Types of materials‏‎ (14:16, 13 September 2019)
  194. Application of ionising radiation in healthcare (old)‏‎ (18:00, 9 October 2019)
  195. Information for patients, family members, carers and the public (old)‏‎ (18:00, 9 October 2019)
  196. Information for healthcare providers (old)‏‎ (18:00, 9 October 2019)
  197. Application of ionising radiation in healthcare‏‎ (18:04, 9 October 2019)
  198. Information for patients, family members, carers and the public‏‎ (18:11, 9 October 2019)
  199. Information for healthcare providers‏‎ (18:21, 9 October 2019)
  200. ICRPædia Guides‏‎ (18:33, 9 October 2019)
  201. List of ICRP Publications on Radiological Protection in Healthcare‏‎ (13:57, 17 October 2019)
  202. Guide to Radiological Protection in Healthcare‏‎ (13:59, 17 October 2019)
  203. The System of Radiological Protection‏‎ (15:15, 23 October 2019)
  204. Quotes from Publications on the System of Radiological Protection‏‎ (17:58, 23 October 2019)
  205. Guide to the System of Radiological Protection‏‎ (15:40, 24 October 2019)
  206. General Information on Radon‏‎ (12:41, 30 October 2019)
  207. System Of Radiation Protection Overview‏‎ (15:02, 4 November 2019)
  208. System of radiation protection module 2‏‎ (15:11, 4 November 2019)
  209. Absorbed, Equivalent, and Effective Dose‏‎ (21:54, 21 November 2019)
  210. Radon For Governments and Employers‏‎ (18:19, 3 December 2019)
  211. Radon For Homeowners and Residents‏‎ (18:19, 3 December 2019)
  212. Guide to Radon‏‎ (07:37, 5 February 2020)
  213. Main Page‏‎ (12:31, 18 November 2020)
  214. Additive risk projection model‏‎ (20:28, 24 February 2021)
  215. Attributable risk‏‎ (20:30, 24 February 2021)
  216. Dicentric chromosome‏‎ (20:31, 24 February 2021)
  217. Effect modifier‏‎ (20:32, 24 February 2021)
  218. Hereditary effect‏‎ (20:33, 24 February 2021)
  219. Low dose‏‎ (20:33, 24 February 2021)
  220. Low dose rate‏‎ (20:35, 24 February 2021)
  221. Multiplicative risk projection model‏‎ (20:36, 24 February 2021)
  222. Ring chromosome‏‎ (20:38, 24 February 2021)
  223. Severe deterministic injury‏‎ (20:38, 24 February 2021)
  224. Somatic effect‏‎ (20:39, 24 February 2021)
  225. Transgenerational effect‏‎ (20:40, 24 February 2021)
  226. Detriment-adjusted risk‏‎ (20:42, 24 February 2021)
  227. Elemental dose‏‎ (20:44, 24 February 2021)
  228. Multistage carcinogenesis model‏‎ (20:50, 24 February 2021)
  229. Mutation component‏‎ (20:51, 24 February 2021)
  230. Oncogene‏‎ (20:52, 24 February 2021)
  231. Population risk‏‎ (20:53, 24 February 2021)
  232. Potentially lethal damage repair‏‎ (20:54, 24 February 2021)
  233. Radiation risk‏‎ (20:55, 24 February 2021)
  234. Relative life lost‏‎ (20:56, 24 February 2021)
  235. Risk model‏‎ (20:57, 24 February 2021)
  236. Sublethal damage repair‏‎ (20:58, 24 February 2021)
  237. Transfer of risk‏‎ (20:59, 24 February 2021)
  238. Tumour suppressor gene‏‎ (21:00, 24 February 2021)
  239. Acute radiation syndrome‏‎ (21:40, 24 February 2021)
  240. Adaptive response‏‎ (21:42, 24 February 2021)
  241. Α/β value‏‎ (21:46, 24 February 2021)
  242. ΓH2AX foci‏‎ (21:46, 24 February 2021)
  243. Informed consent‏‎ (21:49, 24 February 2021)
  244. Supervised area‏‎ (21:51, 24 February 2021)
  245. Access control‏‎ (21:52, 24 February 2021)
  246. Acute exposure‏‎ (21:54, 24 February 2021)
  247. Adventitious source‏‎ (21:55, 24 February 2021)
  248. Authorised discharge‏‎ (21:57, 24 February 2021)
  249. Backscatter factor‏‎ (21:59, 24 February 2021)
  250. Best available techniques‏‎ (22:00, 24 February 2021)

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)